Company intelligence / Profile preview

Everads Therapy

Tel Aviv-Jaffa, Tel Aviv, Israeleverads-therapy.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Everads has developed a proprietary injection technology enabling safe, targeted drug delivery to the back of the eye via the suprachoroidal space. The platform has been validated preclinically with multiple modalities and recently achieved first-in-human results, which were accepted for presentation at ARVO in May 2025. The company claims improved efficacy and safety over existing SCS technologies.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (AAV vectors)Monoclonal antibodies (anti-VEGF)NanoparticlesSmall moleculesCell therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaborations with clinical-stage gene therapy companies and partnerships with pharmaceutical/biotech companies to enable their therapies using Everads’ technology.

Beyond the preview

Go deeper on Everads Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Everads Therapy.